Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;5(11):238.
doi: 10.21037/atm.2017.04.29.

Mesothelioma: recent highlights

Michele Carbone  1 , Haining Yang  1
Affiliations
Review

Mesothelioma: recent highlights

Michele Carbone et al. Ann Transl Med. 2017 Jun.

Abstract

Recent discoveries have elucidated some of the mechanisms responsible for the development of mesothelioma. These discoveries are: (I) the critical role of chronic inflammation in promoting mesothelioma growth, driven by the release of high mobility group box protein-1 (HMGB1) following asbestos deposition in tissues and its potential role as a biomarker to identify asbestos exposed individuals and mesothelioma patients; (II) the discovery that inherited heterozygous germline mutations of the deubiquitylase BRCA-associated protein 1 (BAP1) cause a high incidence of mesothelioma in some families; and that (III) germline BAP1 mutations lower the threshold of asbestos required to cause mesothelioma in mice, evidence of gene X environment interaction. These findings together with the identification of novel serum biomarkers, including HMGB1, Fibulin-3, etc., promise to revolutionize screening and treatment of this malignancy in the coming years.

Keywords: BRCA-associated protein 1 (BAP1); Mesothelioma; SV40; asbestos; erionite; high mobility group box protein-1 (HMGB1).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: M Carbone has pending patent applications on BAP1 and HMGB1 (1 pending, 1 awarded). H Yang has pending patent applications on HMGB1 (1 pending, 1 awarded). M Carbone provides consultation for mesothelioma diagnosis at no cost to patients and colleagues and for a fee to lawyers.

References

    1. Carbone M, Ly BH, Dodson RF, et al. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 2012;227:44-58. 10.1002/jcp.22724 - DOI - PMC - PubMed
    1. Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 2016;48:407-16. 10.1038/ng.3520 - DOI - PubMed
    1. Goldberg M, Imbernon E, Rolland P, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006;63:390-5. 10.1136/oem.2005.023200 - DOI - PMC - PubMed
    1. Carbone M, Shimizu D, Napolitano A, et al. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma. Oncotarget 2016;7:59314-21. - PMC - PubMed
    1. Guo Z, Carbone M, Zhang X, et al. Improving the Accuracy of Mesothelioma Diagnosis in China. J Thorac Oncol 2017;12:714-23. 10.1016/j.jtho.2016.12.006 - DOI - PMC - PubMed